In accordance with a decision by the Board of Directors, Orion Corporation has on 1 March 2016 transferred altogether 144,350 Orion Corporation B-shares held by the company as a share reward for earning periods 2013-2015 and 2015 to the persons belonging to the Share-based Incentive Plan of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 19 March 2013. The price per share of the transferred shares is EUR 31.0826, which is the volume weighted average quotation of the Orion Corporation B-share on 1 March 2016. Accordingly, the total transaction price of the transferred shares is EUR 4,486,773.31.
After the share transfer, the total number of own B-shares held by Orion Corporation is 283 366.
Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 5 February 2013.
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054, mobile +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02101 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2015 amounted to EUR 1,016 million and the Company had about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.
.